An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Cardiovascular disorders; Chronic limb-threatening ischemia; Myocardial infarction; Peripheral arterial disorders; Peripheral ischaemia; Stroke; Thrombosis; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms VOYAGER PAD
- Sponsors Bayer; Bayer HealthCare; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
Most Recent Events
- 04 Apr 2024 According to a Johnson & Johnson media release, analysis from this trial will be presented at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia.
- 01 Apr 2024 Methods, design, and initial results of an angiographic core lab from this study published in the Vascular Medicine
- 14 Nov 2023 According to Janssen media release, results from this trial were presented at the American Heart Association's (AHA) 2023 Scientific Sessions.